Completed × NIH × Neuroectodermal Tumors, Primitive, Peripheral × Clear all Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
4 enrolled 12 charts
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
Phase 1 Completed
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase 1/2 Completed
140 enrolled 23 charts
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase 2 Completed
108 enrolled 14 charts
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Phase 1/2 Completed
40 enrolled 32 charts
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Phase 2 Completed
46 enrolled 13 charts
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Phase 1/2 Completed
78 enrolled 11 charts
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Phase 1/2 Completed
44 enrolled 13 charts
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Phase 2 Completed
40 enrolled 11 charts
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Phase 2 Completed
100 enrolled
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase 2 Completed
120 enrolled
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Phase 2 Completed
7 enrolled 6 charts
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Phase 2 Completed
15 enrolled 7 charts
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
Phase 2 Completed
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
10 enrolled
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
Phase 1 Completed
64 enrolled
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma
Phase 2 Completed
35 enrolled
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
Phase 2 Completed
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase 1 Completed
70 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
Docetaxel in Treating Children With Recurrent Solid Tumors
Phase 2 Completed
20 enrolled
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
Phase 2 Completed
125 enrolled
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
Phase 2 Completed
130 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Phase 1 Completed
90 enrolled
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Phase 1 Completed
26 enrolled